Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      WebMD Announces Fourth Quarter Financial Results

      WebMD Total Revenue Increased 22%; Advertising Revenue Increased 28%

      WebMD Adjusted EBITDA Increased 49%


      News provided by

      WebMD

      Feb 23, 2011, 04:00 ET

      Share this article

      Share this article


      NEW YORK, Feb. 23, 2011 /PRNewswire/ -- WebMD Health Corp. (Nasdaq: WBMD), the leading source of health information, today announced financial results for its fourth quarter ended December 31, 2010.

      “WebMD finished 2010 with another quarter of strong financial and operating performance,” said Wayne Gattinella, President and CEO, WebMD. “We solidified our position as the most recognized and trusted brand of health and wellness information as more than 86 million visitors are engaging with our content each month on both our desktop and mobile platforms."

      For the fourth quarter ended December 31, 2010:

      • Revenue increased 22% to $168.5 million for the fourth quarter, compared to $138.1 million in the prior year period.
      • Earnings before interest, taxes, non-cash and other items ("Adjusted EBITDA") increased 49% to $69.1 million, compared to $46.4 million in the prior year period.
      • Income from continuing operations was $33.8 million compared to $63.6 million in the prior year period. Income from continuing operations would have increased 140%, or $17.1 million, to $29.3 million for the current period, compared to $12.2 million a year ago, without the effect of the following non-operating items (expressed on an after-tax basis): a gain on investments of $8.3 million and a loss on the redemption of the Company’s 3 1/8% convertible notes of $(3.8) million, both in the current period; and, in the prior year period, a net gain of $58.6 million primarily from reversal of valuation allowances related to tax NOLs, a loss of $(6.6) million for merger-related expenses and $(0.5) million attributable to non-controlling interest.
      • Net income was $36.6 million or $0.59 per share, compared to $98.3 million or $1.39 per share in the prior year period. Net income would have increased 140%, or $17.1 million, to $29.3 million for the current period, compared to $12.2 million a year ago, without the effect of the following non-operating items (expressed on an after-tax basis): a gain on investments of $8.3 million, a loss on the redemption of the 3 1/8% Notes of $(3.8) million, and a gain from discontinued operations of $2.8 million, all in the current year period; and, in the prior year period, a net gain of $58.6 million primarily from reversal of valuation allowances related to tax NOLs, a loss of $(6.6) million for merger-related expenses, a gain from discontinued operations of $34.7 million and $(0.5) million attributable to non-controlling interest.

      Revenue Highlights

      Revenue increased 22% to $168.5 million for the fourth quarter, compared to $138.1 million in the prior year period.

      Public portal advertising and sponsorship revenue increased 28% to $147.0 million, compared to $114.9 million in the prior year period. Traffic to the WebMD Health Network continued to grow, reaching a record average of 86.4 million unique users per month and total traffic of 1.8 billion page views during the fourth quarter, increases of 38% and 22%, respectively, from a year ago.

      Private portal services revenue decreased 8% to $21.4 million, compared to $23.2 million in the prior year period. The base of large employers and health plans using WebMD’s private Health and Benefits portals during the fourth quarter was 124.

      Balance Sheet Highlights

      During the fourth quarter, WebMD completed the optional redemption of all of its outstanding 3 1/8% Convertible Notes. Substantially all of these notes converted into approximately 2.4 million shares of WebMD common stock and the remaining notes were redeemed.  WebMD recorded a non-cash pre-tax charge of approximately $6.4 million during the quarter ended December 31, 2010 related to the conversions and redemptions of these Notes.

      As of December 31, 2010, WebMD had $401 million in cash and cash equivalents.

      On January 11, 2011, WebMD completed the private placement of $400 million aggregate principal amount of 2.5% Convertible Notes due 2018. In connection with the private placement, WebMD repurchased 1.9 million shares of its common stock for $100 million. WebMD had $688 million in cash and cash equivalents after completing this transaction.

      Financial Guidance  

      The Company issued financial guidance for 2011 today.

      “We enter 2011 strongly positioned to benefit as biopharma and consumer products companies continue to shift their marketing spend to online channels,” said Gattinella.

      For 2011, WebMD expects:

      • Revenue to be approximately $610 million to $640 million, an increase of 14% to 20% over 2010. These amounts represent expected growth of approximately 16% to 23% in public portal advertising and sponsorship revenue over 2010 while private portal services revenue is expected to be essentially flat compared to 2010.
      • Adjusted EBITDA to be approximately $215 million to $230 million, an increase of 24% to 32% over 2010.
      • Income from continuing operations to be approximately $77 million to $89 million, or $1.22 to $1.40 per diluted share, an increase of 47% to 70% over 2010.  

      For the first quarter of 2011, WebMD expects:

      • Revenue to be in excess of $125 million, an increase of at least 16% over the prior year period. Advertising revenue is expected to increase at least 20% while private portal revenue is expected to be consistent with the prior year period.
      • Adjusted EBITDA to be approximately 27% of revenue.
      • Income from continuing operations to be approximately 7% of revenue.

      WebMD is providing a schedule (attached to this press release) with additional detail.

      Analyst and Investor Conference Call  

      As previously announced, WebMD will hold a conference call with investors and analysts to discuss its fourth quarter results at 4:45 p.m. (Eastern) today. The call can be accessed at www.wbmd.com (in the Investor Relations section). A replay of the audio webcast will be available at the same web address.

      About WebMD

      WebMD Health Corp. (Nasdaq: WBMD) is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers, and health plans through our public and private online portals, mobile platforms and health-focused publications. More than 80 million unique visitors access the WebMD Health Network each month.

      The WebMD Health Network includes WebMD Health, Medscape, MedicineNet, emedicineHealth, RxList, theheart.org, drugs.com and Medscape Education.

      All statements contained in this press release and the related analyst and investor conference call, other than statements of historical fact, are forward-looking statements, including those regarding:   guidance on our future financial results and other projections or measures of our future performance; market opportunities and our ability to capitalize on them; and the benefits expected from new or updated products or services and from other potential sources of additional revenue. These statements speak only as of the date of this press release, are based on our current plans and expectations, and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements.  These risks and uncertainties include those relating to:  market acceptance of our products and services; our relationships with customers and strategic partners; and changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet and information technology industries.  Further information about these matters can be found in our Securities and Exchange Commission filings. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

      This press release, and the accompanying tables, include both financial measures in accordance with accounting principles generally accepted in the United States of America, or GAAP, as well as certain non-GAAP financial measures.  The tables attached to this press release include reconciliations of these non-GAAP financial measures to GAAP financial measures. In addition, an “Explanation of Non-GAAP Financial Measures” is attached to this press release as Annex A.  

      WebMD®, Medscape®, eMedicine®, MedicineNet®, RxList®, Subimo®, Medsite®, Summex® and Medscape® Mobile are trademarks of WebMD Health Corp. or its subsidiaries.

      WEBMD HEALTH CORP.

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (In thousands, except per share data, unaudited)










      Three Months Ended


      Years Ended




      December 31,


      December 31,




      2010


      2009


      2010


      2009











      Revenue


      $ 168,477


      $ 138,073


      $ 534,519


      $ 438,536

      Cost of operations


      51,859


      47,994


      187,831


      165,753

      Sales and marketing


      34,085


      31,478


      120,874


      112,101

      General and administrative


      23,146


      23,802


      85,496


      89,620

      Depreciation and amortization


      7,310


      6,992


      27,578


      28,185

      Interest income


      99


      3,089


      3,949


      9,149

      Interest expense


      1,347


      5,657


      11,453


      23,515

      (Loss) gain on convertible notes


      (6,362)


      -


      (23,332)


      10,120

      Gain (loss) on investments


      13,460


      -


      (9,517)


      -

      Severance and other transaction expenses


      -


      11,066


      -


      11,066

      Other income (expense), net


      20


      (425)


      (72)


      (1,369)

      Income from continuing operations before income










      tax provision (benefit)


      57,947


      13,748


      72,315


      26,196


      Income tax provision (benefit)


      24,183


      (50,413)


      20,043


      (45,491)

      Consolidated income from continuing operations


      33,764


      64,161


      52,272


      71,687


      Consolidated income from discontinued operations, net of tax


      2,824


      34,659


      1,800


      49,354

      Consolidated net income inclusive of noncontrolling interest


      36,588


      98,820


      54,072


      121,041


      Income attributable to noncontrolling interest


      -


      (524)


      -


      (3,705)

      Net income attributable to Company stockholders


      $   36,588


      $   98,296


      $   54,072


      $ 117,336











      Amounts attributable to Company stockholders:










      Income from continuing operations


      $   33,764


      $   63,637


      $   52,272


      $   67,018


      Income from discontinued operations


      2,824


      34,659


      1,800


      50,318

      Net income attributable to Company stockholders


      $   36,588


      $   98,296


      $   54,072


      $ 117,336











      Basic income per common share:










      Income from continuing operations


      $       0.58


      $       1.19


      $       0.93


      $       1.40


      Income from discontinued operations


      0.05


      0.65


      0.04


      1.05

      Net income attributable to Company stockholders


      $       0.63


      $       1.84


      $       0.97


      $       2.45











      Diluted income per common share:










      Income from continuing operations


      $       0.55


      $       0.92


      $       0.85


      $       1.21


      Income from discontinued operations


      0.04


      0.47


      0.03


      0.86

      Net income attributable to Company stockholders


      $       0.59


      $       1.39


      $       0.88


      $       2.07











      Weighted-average shares outstanding used in










      computing  income per common share:









           Basic


      57,505


      52,688


      55,328


      47,400

           Diluted


      62,330


      71,945


      62,228


      57,740



      WEBMD HEALTH CORP.

      CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION

      (In thousands, unaudited)




















      Three Months Ended


      Years Ended




      December 31,


      December 31,




      2010


      2009


      2010


      2009

      Revenue










      Public portal advertising and sponsorship


      $ 147,042


      $ 114,875


      $ 446,969


      $ 347,570


      Private portal services


      21,435


      23,198


      87,550


      90,966




      $ 168,477


      $ 138,073


      $ 534,519


      $ 438,536











      Earnings before interest, taxes, non-cash










      and other items ("Adjusted EBITDA") (a)


      $   69,082


      $   46,428


      $ 173,618


      $ 112,274











      Interest, taxes, non-cash and other items  (b)










      Interest income


      99


      3,089


      3,949


      9,149


      Interest expense


      (1,347)


      (5,657)


      (11,453)


      (23,515)


      Income tax (provision) benefit


      (24,183)


      50,413


      (20,043)


      45,491


      Depreciation and amortization


      (7,310)


      (6,992)


      (27,578)


      (28,185)


      Non-cash stock-based compensation


      (9,695)


      (11,629)


      (33,300)


      (39,412)


      Non-cash advertising


      -


      -


      -


      (1,753)


      (Loss) gain on convertible notes


      (6,362)


      -


      (23,332)


      10,120


      Gain (loss) on investments


      13,460


      -


      (9,517)


      -


      Severance and other transaction expenses


      -


      (11,066)


      -


      (11,066)


      Other income (expense), net


      20


      (425)


      (72)


      (1,416)

      Consolidated income from continuing operations


      33,764


      64,161


      52,272


      71,687


      Consolidated income from discontinued operations, net of tax


      2,824


      34,659


      1,800


      49,354

      Consolidated net income inclusive of noncontrolling interest


      36,588


      98,820


      54,072


      121,041


      Income attributable to noncontrolling interest


      -


      (524)


      -


      (3,705)

      Net income attributable to Company stockholders


      $   36,588


      $   98,296


      $   54,072


      $ 117,336











      (a)  See Annex A-Explanation of Non-GAAP Financial Measures.  

      (b)  Reconciliation of Adjusted EBITDA to consolidated income from continuing operations.  



      WEBMD HEALTH CORP.

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (In thousands, unaudited)













      December 31, 2010


      December 31, 2009

      Assets





      Cash and cash equivalents


      $ 400,501


      $    459,766

      Accounts receivable, net


      134,448


      118,155

      Prepaid expenses and other current assets


      12,161


      11,419

      Investments


      -


      9,932

      Deferred tax assets


      23,467


      -

             Total current assets


      570,577


      599,272






      Investments


      -


      338,446

      Property and equipment,  net


      61,516


      52,194

      Goodwill


      202,104


      202,104

      Intangible assets, net


      22,626


      26,020

      Deferred tax assets


      71,125


      50,789

      Other assets


      14,254


      19,723

      Total Assets


      $ 942,202


      $ 1,288,548






      Liabilities and Equity





      Accrued expenses


      $   53,181


      $      63,721

      Deferred revenue


      97,043


      98,474

      1.75% convertible notes


      -


      264,583

      Deferred tax liabilities


      -


      12,955

      Liabilities of discontinued operations


      17,327


      34,197

           Total current liabilities


      167,551


      473,930






      3 1/8% convertible notes, net of discount of $22,641 at December 31, 2009


      -


      227,659

      Other long-term liabilities


      21,756


      22,191






      Stockholders' equity


      752,895


      564,768






      Total Liabilities and Equity


      $ 942,202


      $ 1,288,548



      WEBMD HEALTH CORP.

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (In thousands, unaudited)























      Years Ended







      December 31,







      2010


      2009

      Cash flows from operating activities:






      Consolidated net income inclusive of noncontrolling interest


      $   54,072


      $ 121,041


      Adjustments to reconcile consolidated net income inclusive of noncontrolling






       interest to net cash provided by operating activities:







      Consolidated income from discontinued operations, net of tax


           (1,800)


         (49,354)



      Depreciation and amortization


           27,578


           28,185



      Non-cash interest, net


             5,594


           10,205



      Non-cash advertising


                   -  


             1,753



      Non-cash stock-based compensation


           33,300


           39,412



      Deferred income taxes


              (403)


         (42,143)



      Loss (gain) on convertible notes


           23,332


         (10,120)



      Loss on investments


             9,517


                   -  



      Changes in operating assets and liabilities:








      Accounts receivable


         (16,292)


         (25,073)




      Prepaid expenses and other, net


             4,617


             6,979




      Accrued expenses and other long-term liabilities


                213


             7,677




      Deferred revenue


           (1,431)


           18,861





      Net cash provided by continuing operations


         138,297


         107,423





      Net cash (used in) provided by discontinued operations


         (16,474)


                305





      Net cash provided by operating activities


         121,823


         107,728










      Cash flows from investing activities:






      Proceeds from sales of available-for-sale securities


         361,852


             2,300


      Proceeds received from ARS option


           10,467


                   -  


      Purchases of property and equipment


         (32,254)


         (17,886)


      Proceeds (payments made) from the sale of discontinued operations


           (1,430)


           72,318





      Net cash provided by continuing operations


         338,635


           56,732





      Net cash used in discontinued operations


                   -  


           (3,552)





      Net cash provided by investing activities


         338,635


           53,180










      Cash flows from financing activities:






      Proceeds from exercise of stock options


           59,825


           42,898


      Cash used for withholding taxes due on stock-based awards


         (86,533)


         (17,645)


      Repurchases of convertible notes


         (94,525)


       (123,857)


      Purchase of treasury stock under repurchase program and tender offers


       (420,948)


       (228,402)


      Cash paid for merger related costs


                   -  


           (5,021)


      Excess tax benefit on stock-based awards


           22,458


                480





      Net cash used in financing activities


       (519,723)


       (331,547)

      Effect of exchange rates on cash


                   -  


                557

      Net decrease in cash and cash equivalents


         (59,265)


       (170,082)

      Cash and cash equivalents at beginning of period


         459,766


         629,848

      Cash and cash equivalents at end of period


      $ 400,501


      $ 459,766



      WEBMD HEALTH CORP.

      CONSOLIDATED NET INCOME ATTRIBUTABLE TO COMPANY STOCKHOLDERS

      (In thousands, except per share data, unaudited)
























      Three Months Ended


      Years Ended




      December 31,


      December 31,




      2010


      2009


      2010


      2009











      Numerator:









      Income from continuing operations


      $33,764


      $63,637


      $52,272


      $67,018


      Effect of participating non-vested restricted stock


      (339)


      (886)


      (601)


      (787)

      Income from continuing operations -- Basic


      33,425


      62,751


      51,671


      66,231


      Interest expense on 1.75% Convertible Notes, net of tax


      -


      876


      1,469


      3,714


      Interest expense on 3 1/8% Convertible Notes, net of tax


      809


      2,472


      -


      -


      Effect of dilutive securities of subsidiary


      -


      (57)


      -


      (343)

      Income from continuing operations - Diluted


      $34,234


      $66,042


      $53,140


      $69,602











      Income from discontinued operations net of tax


      $  2,824


      $34,659


      $  1,800


      $50,318


      Effect of participating non-vested restricted stock


      (28)


      (483)


      (21)


      (591)

      Income from discontinued operations --Basic


      2,796


      34,176


      1,779


      49,727


      Effect of dilutive securities of subsidiary


      -


      -


      -


      53

      Income from discontinued operations --Diluted


      $  2,796


      $34,176


      $  1,779


      $49,780











      Denominator:









      Weighted-average shares -- Basic


      57,505


      52,688


      55,328


      47,400


      Employee stock options and restricted stock


      2,651


      4,470


      3,706


      2,265


      1.75% Convertible Notes


      -


      7,640


      3,194


      8,075


      3 1/8% Convertible Notes


      2,174


      7,147


      -


      -

      Adjusted weighted-average shares after assumed conversions -- Diluted


      62,330


      71,945


      62,228


      57,740











      Basic income per common share:










      Income from continuing operations


      $    0.58


      $    1.19


      $    0.93


      $    1.40


      Income from discontinued operations


      0.05


      0.65


      0.04


      1.05

      Net income attributable to Company stockholders


      $    0.63


      $    1.84


      $    0.97


      $    2.45











      Diluted income per common share:










      Income from continuing operations


      $    0.55


      $    0.92


      $    0.85


      $    1.21


      Income from discontinued operations


      0.04


      0.47


      0.03


      0.86

      Net income attributable to Company stockholders


      $    0.59


      $    1.39


      $    0.88


      $    2.07



      WebMD Health Corp.

      2011 Financial Guidance

      (in millions, except per share amounts)











      Year Ending



      December 31, 2011



      Guidance Range






      Revenue


      $ 610.0


      $ 640.0






      Earnings before interest, taxes, depreciation, amortization





       and other non-cash items ("Adjusted EBITDA") (a)


      $ 215.0


      $ 230.0






      Interest, taxes, depreciation, amortization and other





       non-cash items (b)





      Interest income


             0.5


             0.5

      Interest expense


         (11.5)


         (11.5)

      Depreciation and amortization


         (30.0)


         (28.0)

      Non-cash stock-based compensation


         (41.0)


         (38.0)

      Pre-tax income from continuing operations


         133.0


         153.0






      Income tax provision


         (56.0)


         (64.0)






      Income from continuing operations


      $   77.0


      $   89.0











      Income from continuing operations per share :





        Basic


      $   1.27


      $   1.47

        Diluted


      $   1.22


      $   1.40






      Weighted-average shares outstanding used in computing income





          from continuing operations per common share:





       Basic


           60.0


           60.0

       Diluted


           68.0


           68.0








      (a) See Annex A - Explanation of Non-GAAP Financial Measures


      (b) Reconciliation of Adjusted EBITDA to consolidated income from continuing operations


      Additional information regarding forecast for the first quarter of 2011:

      • Revenue is forecasted to be in excess of $125 million in the quarter ending March 31, 2011
      • Adjusted EBITDA as a percentage of revenue is forecasted to be approximately 27% in the quarter ending March 31, 2011
      • Income from continuing operations as a percentage of revenue is forecasted to be approximately 7% in the quarter ending March 31, 2011

      Additional information regarding full year forecast:

      • Income tax rate for 2011 is forecasted to be approximately 42% of pretax income.  
      • The distribution of the annual revenue is expected to be approximately 85% public portals advertising and sponsorship and  15% private portal licensing.  Quarterly revenue distributions may vary from this annual estimate
      • 2011 guidance excludes any gains or losses related to investments / convertible notes.  

      Additional information regarding full year income per share calculation:

      • Basic income per share: Reflects a reduction to income from continuing operations of $0.6 million to consider the effect of restricted stock.
      • Diluted income per share: Reflects an increase to income from continuing operations of $6.1 million for the interest expense (net of tax) on the 2.5% Notes of $6.7 million, offset by $0.6 million to consider the effect of restricted stock. The diluted share count of 68 million includes the weighted impact of 6 million shares related to the 2.5% Notes.


      ANNEX A

      Explanation of Non-GAAP Financial Measures

      (All dollar amounts in thousands)

      The accompanying WebMD Health Corp. press release and financial tables include both financial measures in accordance with U.S. generally accepted accounting principles, or GAAP, as well as non-GAAP financial measures.  The non-GAAP financial measures represent earnings before interest, taxes, non-cash and other items (which we refer to as "Adjusted EBITDA") and related per share amounts.  Adjusted EBITDA should be viewed as supplemental to, and not as an alternative for, "consolidated income (loss) from continuing operations" or "net income (loss) attributable to Company stockholders" calculated in accordance with GAAP.  The accompanying financial tables include reconciliations of non-GAAP financial measures to GAAP financial measures.  

      Adjusted EBITDA is used by our management as an additional measure of our company's performance for purposes of business decision-making, including developing budgets, managing expenditures, and evaluating potential acquisitions or divestitures.  Period-to-period comparisons of Adjusted EBITDA help our management identify additional trends in our company's financial results that may not be shown solely by period-to-period comparisons of consolidated income (loss) from continuing operations or net income (loss) attributable to Company stockholders.  In addition, we use Adjusted EBITDA in the incentive compensation programs applicable to many of our employees in order to evaluate our company's performance.  Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items, particularly those items that are recurring in nature.  In order to compensate for those limitations, management also reviews the specific items that are excluded from Adjusted EBITDA, but included in consolidated income (loss) from continuing operations or net income (loss) attributable to Company stockholders, as well as trends in those items.  The amounts of those items are set forth, for the applicable periods, in the reconciliations of Adjusted EBITDA to consolidated income (loss) from continuing operations or to net income (loss) attributable to Company stockholders that accompany our press releases and disclosure documents containing non-GAAP financial measures, including the reconciliations contained in the accompanying financial tables.

      We believe that the presentation of Adjusted EBITDA is useful to investors in their analysis of our results for reasons similar to the reasons why our management finds it useful and because it helps facilitate investor understanding of decisions made by management in light of the performance metrics used in making those decisions.  In addition, as more fully described below, we believe that providing Adjusted EBITDA, together with a reconciliation of Adjusted EBITDA to consolidated income (loss) from continuing operations or to net income (loss) attributable to Company stockholders, helps investors make comparisons between our company and other companies that may have different capital structures, different effective income tax rates and tax attributes, different capitalized asset values and/or different forms of employee compensation.  However, Adjusted EBITDA is intended to provide a supplemental way of comparing our company with other public companies and is not intended as a substitute for comparisons based on "consolidated income (loss) from continuing operations" or "net income (loss) attributable to Company stockholders" calculated in accordance with GAAP.  In making any comparisons to other companies, investors need to be aware that companies use different non-GAAP measures to evaluate their financial performance.  Investors should pay close attention to the specific definition being used and to the reconciliation between such measures and the corresponding GAAP measures provided by each company under applicable SEC rules.

      The following is an explanation of the items excluded by us from Adjusted EBITDA but included in consolidated income (loss) from continuing operations:

      • Depreciation and Amortization.  Depreciation and amortization expense is a non-cash expense relating to capital expenditures and intangible assets arising from acquisitions that are expensed on a straight-line basis over the estimated useful life of the related assets.  We exclude depreciation and amortization expense from Adjusted EBITDA because we believe that (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired tangible and intangible assets.  Accordingly, we believe that this exclusion assists management and investors in making period-to-period comparisons of operating performance.  Investors should note that the use of tangible and intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation and should also note that such expense will recur in future periods.

      • Stock-Based Compensation Expense.  Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees.  We believe that excluding the effect of stock-based compensation from Adjusted EBITDA assists management and investors in making period-to-period comparisons in its operating performance because (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions.  Additionally, we believe that excluding stock-based compensation from Adjusted EBITDA assists management and investors in making meaningful comparisons between our operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation.  Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods.  Investors should also note that such expenses will recur in the future.  Stock-based compensation expenses included in the Consolidated Statement of Operations are summarized as follows:







      Three Months Ended


      Year Ended






      December 31,


      December 31,






      2010

      2009


      2010

      2009








      Non-cash stock-based compensation included in:







      Cost of operations


      $    2,058

      $   1,802


      $    7,211

      $    6,723


      Sales and marketing


      $    2,284

      $   2,570


      $    8,033

      $    8,069


      General and administrative


      $    5,353

      $   7,257


      $  18,056

      $  24,620


      Income from discontinued operations


      $         ―

      $        39


      $         ―

      $       693




      • Non-Cash Advertising Expense.  This expense relates to the usage of non-cash advertising obtained from News Corporation ("Newscorp") in exchange for equity securities issued in 2000.  The advertising was available only on various Newscorp properties, primarily its television network and cable channels, without any cash cost to us and expired in 2009.  We exclude this expense from Adjusted EBITDA (i) because it is a non-cash expense, (ii) because it is incremental to other non-television cash advertising expense that we may otherwise incur and (iii) to assist management and investors in comparing its operating results over multiple periods.  Investors should note that it is likely that we derived some benefit from such advertising. Non-cash advertising expenses included in the Consolidated Statement of Operations in Sales and Marketing expense were $1,753 for the year ended December 31, 2009.  

      • Interest Income and Expense.  Interest income is associated with the level of marketable debt securities and other interest bearing accounts in which we invest, as well as with interest expense arising from our company's capital structure (including non-cash interest expense relating to our convertible notes).  Interest income and expense varies over time due to a variety of financing transactions and due to acquisitions and divestitures that we have entered into or may enter into in the future.  We have, in the past, issued convertible debentures, repurchased shares in cash tender offers and repurchased shares and convertible debentures through other repurchase transactions, and completed the divestiture of certain businesses.  We exclude interest income and interest expense from Adjusted EBITDA (i) because these items are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different capital structures.  Investors should note that interest income and expense will recur in future periods.  The following provides detail of the components of interest expense of our convertible notes:







      Three Months Ended


      Year Ended






      December 31,


      December 31,






      2010

      2009


      2010

      2009








      Non-cash interest expense







      1.75% Convertible Notes


      $          ―

      $      302


      $       885

      $  1,272


      3 1/8% Convertible Notes


      $        732

      $   2,166


      $    4,996

      $  8,933


      Cash interest expense








      1.75% Convertible Notes


      $         ―

      $   1,158


      $    1,564

      $  4,918


      3 1/8% Convertible Notes


      $       615

      $   1,956


      $    4,007

      $  8,310




      • Income Tax Provision (Benefit).  We maintain a valuation allowance on a portion of our net deferred tax assets (including our net operating loss carryforwards), the amount of which may change from quarter to quarter based on factors that are not directly related to our results for the quarter.  The valuation allowance is either reversed through the statement of operations or additional paid-in capital.  The timing of such reversals has not been consistent and as a result, our income tax expense can fluctuate significantly from period to period in a manner not directly related to our operating performance.  We exclude the income tax provision (benefit) from Adjusted EBITDA (i) because we believe that the income tax provision (benefit) is not directly attributable to the underlying performance of our business operations and, accordingly, its exclusion assists management and investors in making period-to-period comparisons of operating performance and (ii) to assist management and investors in making comparisons to companies with different tax attributes.  Investors should note that income tax provision (benefit) will recur in future periods.

      • Other Items.  We engage in other activities and transactions that can impact our overall consolidated income (loss) from continuing operations.  In recent periods, these other items have included, but were not limited to, (i) legal expenses relating to the ongoing Department of Justice investigation, (ii) gain or loss on repurchases and conversions of our convertible notes, (iii) a reduction of certain sales and use tax contingencies resulting from the expiration of certain applicable statutes of limitations, (iv) advisory expenses relating to the merger of HLTH Corporation into our company in 2009, and  (v) gain or loss on investments.  We exclude these other items from Adjusted EBITDA because we believe these activities or transactions are not directly attributable to the performance of our business operations and, accordingly, their exclusion assists management and investors in making period-to-period comparisons of operating performance.  Investors should note that some of these other items may recur in future periods.

      SOURCE WebMD

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.